You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Skip to content

This site is a non-promotional medical portal for Kenya Healthcare Professionals. Not a healthcare professional? Visit our Public site

GSK Logo
Search

Report adverse event

GSK Logo

For Kenya Healthcare Professionals

  • GSK Medical
  • Therapy Areas
    • Vaccines
    • Respiratory
  • Contact us
Vaccines
  • Vaccinology
    • Introduction
    • Direct Benefits
    • Indirect and overall benefits
    • Economic Benefits
    • Conclusions
  • Vaccinology
    • Introduction
    • Direct Benefits
    • Indirect and overall benefits
    • Economic Benefits
    • Conclusions

Menu

  1. GSK Medical>
  2. Therapy Areas>
  3. Vaccines>
  4. Vaccinology>
  5. Understanding AS01 Adjuvant MoA in Vx

Understanding AS01 Adjuvant Mode of Action in Vaccines

The use of adjuvants is required in some vaccine formulations to provide help to the antigen in order to enhance the immune response.1

Following induction of different adjuvants into vaccines in the 90’s, the need to combine adjuvants in so called adjuvant systems to enhance immunogenicity became apparent.2 The following video will highlight the mode of action of one specific adjuvant system: AS013-8:

References

  1. Garcon N, Leroux-Roels G, Cheng WF. Vaccine adjuvants. Understanding modern vaccines: perspectives in vaccinology. Elsevier; 2011. p. 89–113.
  2. Laupèze, B., Hervé, C., Di Pasquale, A., Tavares Da Silva, F. Adjuvant Systems for vaccines: 13 years of post-licensure experience in diverse populations have progressed the way adjuvanted vaccine safety is investigated and understood. Vaccine, 2019, 37(38), pp. 5670–5680.
  3. Didierlaurent AM, Collignon C, Bourguignon P, et al. Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells. J Immunol 2014; 193:1920–1930.
  4. Leo O, Cunningham A & Stern PL. Vaccine Immunology. Understanding Modern Vaccines: Perspectives in Vaccinology. Elsevier vol.2011; 25–59.
  5. Dendouga N, Fochesato M, Lockman L, et al. Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice. Vaccine 2012; 30:3126–3135.
  6. Geissmann F, Manz MG, Jung S, et al. Development of monocytes, macrophages, and dendritic cells. Science 2010; 327:656–661.
  7. Rezk SA & Weis L. Lymph Nodes. John Wiley & sons. Available at : https://onlinelibrary.wiley.com/doi/10.1002/9780470015902.a0000525.pub3. 2015.

Material supplied by the above-country business unit to LOCs for localisation must be subject to local Medical and/or Regulatory review and approval prior to use and/or external distribution.

LOCs to insert local adverse events reporting procedure.

© 2022 GSK group of companies or its licensor. GlaxoSmithKline Biologicals SA. Rixensart, Belgium.

NX-GBL-GVX-WCNT-220016 | November 2022

Get in touch

 

Contact us

  • Report adverse event
  • Sitemap
  • Terms of use
  • Privacy Notice

©2024 GSK group of companies or its licensor. GlaxoSmithKline Export Limited, at 79 New Oxford Street, London, WC1A 1DG, UK.